AstraZeneca's Tozorakimab Cuts COPD Flare-Ups across the Board

New late-stage data show AstraZeneca’s tozorakimab delivering a clear reduction in COPD flare-ups across a broad patient population.

Patients who received the monoclonal antibody experienced 29 to 34 percent fewer moderate-to-severe exacerbations than those on placebo over a full year.

Researchers presented the findings in Barcelona and published them simultaneously in The New England Journal of Medicine.

The drug works by targeting interleukin-33, a protein that drives airway inflammation and mucus production.

It showed benefit in current and former smokers alike, regardless of lung-function severity or eosinophil levels. Safety remained comparable to placebo, giving doctors a potential new tool for patients who continue to struggle with repeated flare-ups despite standard care.

Key Results That Stand Out

• Tozorakimab reduced moderate-to-severe COPD exacerbations by 29–34 percent versus placebo.
• Average event rates fell to 1.41 and 1.44 per year on the drug compared with 2.00 and 2.03 on placebo.
• The two trials enrolled 1,750 current or former smokers who had experienced flares in the previous year.
• Every participant continued standard therapy while receiving either tozorakimab or placebo.
• Doctors inject the antibody under the skin once every four weeks.
• Benefit held steady across smoking status, lung-impairment severity, and eosinophil counts.
• Overall safety profiles stayed generally similar between the two groups.

Why Fewer Flare-Ups Matter 

COPD exacerbations damage lung function, lower quality of life, and worsen long-term outcomes. Study leader Dr. Frank Sciurba of the University of Pittsburgh stresses that cutting these events ranks among the most important treatment goals.

Each flare-up can send patients to the hospital, accelerate disease progression, and leave them more vulnerable to the next attack. By lowering the frequency of moderate-to-severe events, tozorakimab directly addresses this central problem. The consistent reduction across different patient subgroups suggests the drug can help a broad slice of the COPD population rather than only a narrow biological niche.

Also Read: How Biologics and Complex Therapies Are Reshaping CDMO Strategy

A New Mechanism Enters the Picture

Most existing COPD therapies focus on bronchodilation or broad anti-inflammatory effects. Tozorakimab takes a more targeted route by blocking interleukin-33. This approach interrupts a specific pathway linked to both inflammation and excess mucus.

The fact that the benefit appeared independent of eosinophil levels is particularly noteworthy. Many current biologics work best in patients with high eosinophils, whereas tozorakimab performed equally well across the eosinophil spectrum. That wider applicability could expand treatment options for patients whose disease does not fit the classic high-eosinophil profile.

What Comes Next for Patients and Regulators

Sciurba notes that the U.S. Food and Drug Administration is now reviewing the data for possible approval outside clinical trials. He describes the results as encouraging for people who often struggle simply to breathe.

If regulators clear the drug, clinicians will gain an additional safe therapy that they can add to standard care and administer once a month by subcutaneous injection. The combination of meaningful exacerbation reduction, broad efficacy, and a familiar safety profile positions tozorakimab as a potentially important advance in COPD management.